As the transmission blocking potential of these Eimeria targets are assessed in future studies, wider implications can be expected in related Coccidia, like Toxoplasma, where transmission blocking remains a relatively unexplored control strategy.
To further explore the blocking potential of Cit573, a retrieval assay was performed, that is, the ability of the peptide to compete with already CCP2-bound ACPA was tested.
The transmission blocking potential of PQ has also been suggested as a strategy to reduce the spread of artemisinin resistant parasites in Southeast Asia (Breman 2012).
However, the cord blood antibodies completely lacked blocking potential of both VLPs (Fig. 1).
To initially investigate the parasite inhibitory and thereby transmission-blocking potential of the PfGAP50-cTPH-specific antibodies a zygote inhibition assay was performed by the addition of PfGAP50-cTPH-specific rabbit immune IgG to gametocyte cultures.
In the present work, we added various substituents at C-3 of this moiety to block potential β-oxidation of the 5-oxo-valerate side chain, and investigated the structure-activity relationships of the resulting novel β-oxidation-resistant antagonists.
Similar results were obtained in the presence of saturating concentrations of mAb IV.3 (1 μg/mL) to block potential antibody binding of the platelet IgG receptor FcγRIIa (not shown).
Various drugs were added to block potential sources of ROS; the non-specific NADPH oxidase inhibitor diphenyleneiodonium (DPI, 10 µM); the NOS inhibitor, N-nitro-L-arginine methyl ester hydrochloride (L-NAME, 100 µM); the mitochondrial site I electron transport inhibitor, rotenone (20 µM); and the xanthine oxidase inhibitor, oxypurinol (100 µM).
Finally, it is the largest cohort treated with the novel disease specific therapy concept using the Prolactin blocker bromocriptine in addition to the standard therapy for heart failure aiming to block potential adverse effects of the angiostatic 16 kDa Prolactin.
The baths contained Krebs solution, which routinely contained indomethacin (1 μM) and Nω-nitro-L-arginine (l-NNA, 100 μM) to block potential residual effects of the endothelium and to eliminate possible time dependent effects due to activation of inducible nitric oxide synthase (iNOS) and/or cyclooxygenase.
